Dr. Peter Balazs
Coverage of Dr. Peter Balazs in the Nexus archive.
- Weight-loss drugs may improve job prospects and dating odds for one group
A study by Rebecca Diamond found that GLP-1 weight-loss drugs may improve women’s job prospects and dating odds. The research, using the Understanding America Study, showed single women who lost weight with GLP-1s saw a 29% rise in marriage/cohabitation and 27% increase in employment rates after 18 months, excluding those using the drugs for diabetes.
- Ozempic users may be making a major weight-loss mistake, new study suggests
A new study suggests that adults taking GLP-1 medications like Ozempic or Wegovy for weight loss are significantly reducing their physical activity, with decreases in daily steps and moderate-to-vigorous exercise. Researchers emphasize that exercise remains essential for preserving strength and long-term health when using these drugs, despite the observed decline in activity.
- Secret to weight loss may be hiding in your gut, new study suggests
A study in Nature Medicine found that pasteurized Akkermansia muciniphila MucT, a gut bacterium, helped overweight and obese adults regain less weight after dieting compared to a placebo. Participants taking the bacterium regained an average of 2.6 pounds versus 7.1 pounds in the placebo group, though researchers noted limitations like a small sample size and short duration. Dr. Peter Balazs highlighted the treatment's potential to support weight maintenance by reducing biological signals that promote fat regain.
- This could be why your weight-loss medication isn’t delivering results
A study in Nature found genetic variations in the GLP1R and GIPR genes influence the effectiveness and side effects of GLP-1 receptor agonists like semaglutide and tirzepatide. Patients with specific gene variants experienced modest weight loss boosts and increased nausea risks, highlighting potential for personalized treatment approaches.